Close Menu

People in the News

Sep 14, 2020

Veracyte: Richard Kloos

Veracyte has promoted Richard Kloos to executive medical director, overseeing the company's global medical affairs in all clinical areas addressed by its genomic tests. Kloos previously served as senior medical director of endocrinology at Veracyte, which he joined in 2012. He was previously a professor of endocrinology and metabolism, and nuclear medicine at Ohio State University, and was attending physician at the OSU Comprehensive Care Center. He was also codirector of the OSU Thyroid Cancer Unit and served a four-year term as secretary and chief operating officer for the American Thyroid Association.

Sep 14, 2020

Thermo Fisher Scientific: Joseph Holmes, Peter Hornstra

Joseph Holmes has been elected as VP and chief accounting officer of Thermo Fisher Scientific, effective March 31, 2021. He will succeed Peter Hornstra, who will retire from the company March 31. Holmes is currently senior director of technical accounting at Thermo Fisher, a position he assumed when he joined the company in 2017. Previously, he was director of technical accounting and reporting at St. Jude Medical, which was acquired by Abbott Laboratories in 2017.

Sep 14, 2020

Vizgen: Terry Lo, Peidong Wang

Spatial gene expression analysis startup Vizgen has appointed Terry Lo as president and CEO, effective immediately. He has more than two decades of experience in developing commercialization strategies for life sciences companies, Vizgen said. Lo comes to Vizgen from Akoya Biosciences, where he was president. He has also held executive positions at PerkinElmer, Roche, Hologic, and Bristol-Myers Squibb. Lo has an MBA from the University of Chicago and a masters' degree in microbiology from Virginia Tech.

Interim CEO Peidong Wang will remain at Vizgen as VP of engineering.

Sep 14, 2020

Pacific Biosciences: Susan Kim

Pacific Biosciences has appointed Susan Kim as CFO, effective Sept. 28, 2020. She brings 20 years of senior-level finance and operations experience. Kim most recently served as CFO for App Annie and Katerra. She has also held leadership roles at KLA Corporation, Morgan Stanley, and Advanced Micro Devices. Kim holds MBA and masters of engineering management degrees from Northwestern University.

Sep 14, 2020

GenMark Diagnostics: Brian Mitchell

GenMark Diagnostics said in a filing with the US Securities and Exchange Commission that Brian Mitchell, its senior vice president of operations, is no longer employed by the company.

Sep 11, 2020

Catalog DNA: David Turek

Catalog DNA, a startup pursuing DNA data storage and computing technology, has named David Turek as CTO. He will oversee technical strategy, business development, and collaborations. Turek joins Catalog after 20 years at IBM, where he led commercialization of the Deep Blue supercomputer, which famously defeated chess legend Garry Kasparov in a series of matches held in 1997. Turek was also involved in creating IBM's Roadrunner and Blue Gene supercomputers.

Sep 11, 2020

Invitae: Kimber Lockhart

Invitae has appointed Kimber Lockhart to its board of directors effective Sept. 10. Lockhart has been chief technology officer at technology-enabled primary care organization One Medical since 2015. From 2009 to 2014, she held various engineering leadership positions at Box, an online file sharing service. Lockhart joined Box in 2009, when it acquired Increo Solutions, a document rendering and collaboration technlogy firm she cofounded and led as CEO.  

Sep 10, 2020

Biofidelity: Heiner Dreismann

Biofidelity has appointed Heiner Dreismann as the firm's chairman. Prior to Biofidelity, Dreismann served as president and CEO of Roche Molecular Systems. He currently serves on the board of several public and private life sciences and healthcare firms in the US, Europe, and Israel. 

Sep 10, 2020

Myriad Genetics: Rashmi Kumar

Myriad Genetics' board of directors has elected Rashmi Kumar, senior VP and global chief information officer at Hewlett Packard, as its new member and appointed her to the audit and finance committee. With the election of Kumar, Myriad's board now has 12 members. Kumar previously worked at McKesson Corporation as senior VP, chief information officer, and US pharmaceutical and global chief data officer. 

Sep 10, 2020

CareDx: Kashif Rathore, Ryan Phan, Sean Grant, and Danielle Scelfo

CareDx has appointed Kashif Rathore as senior VP of digital business, Ryan Phan as VP of lab operations, Sean Grant as VP of strategy and business development, and Danielle Scelfo as VP of market access and health policy.

Rathore joins CareDx from Cerner, where he held various senior leadership roles. In addition to his most recent role as VP of interoperability, Rathore served in the consulting and technology lines of Cerner's businesses. 

Phan joins CareDx from Kaiser Permanente, where he served as managing director and head of regional molecular genetics and cytogenetics laboratories. He has led multiple strategic laboratory expansions and developed and implemented clinical testing programs. 

Grant joins CareDx from Citigroup Global Capital Markets, where he served as a VP in the investment banking healthcare division. At Citigroup, Grant specialized in raising public and private capital and executed a broad range of transactions, including M&A, for many life sciences companies around the world. 

Scelfo joins CareDx from Hologic, where she served as senior director of health policy and reimbursement. She has more than 25 years of health policy and strategic market access experience, including roles at Genomic Health and Adaptive Biotechnologies.

Sep 09, 2020

Sherlock Biosciences: Martin Madaus

Sherlock Biosciences has appointed Martin Madaus as chief operations officer. Madaus brings nearly 30 years of industry experience leading diagnostics companies across all stages of development through commercialization, and will lead Sherlock's business operations functions while supporting the company to scale to a fully functional commercial organization.

Madaus most recently served as interim CEO and executive chairman at Ultivue and Emulate Bio. He also served as chairman and CEO of Ortho Clinical Diagnostics from 2014 to 2019, leading the buyout through the Carlyle Group, where he continues to serve as operating executive. Prior to that, he served as president, chairman, and CEO of Millipore, which was acquired by Merck KGaA, and as CEO of Roche Diagnostics North America. Madaus also has extensive public and private company board experience and currently serves on the boards of Quanterix, Ultivue, Emulate Bio, and Candela Medical.

Sep 09, 2020

Bruker: Bonnie Anderson

Bruker has appointed Bonnie Anderson to the firm's board of directors. She is a cofounder of Veracyte and currently serves as the firm's board chairman and CEO. Prior to Veracyte, Anderson spent 18 years at Beckman Coulter.  

Sep 08, 2020

Lifebit: Frank Seo

Lifebit has hired Frank Seo as general manager. Seo, who will run the London-based company's commercial operations and oversee global expansion plans, comes to Lifebit from life sciences software vendor Veeva Systems. Most recently, he was VP of enterprise customer relationship management strategy at Veeva. He also spent nearly nine years as VP of business development at the firm and previously served as its general manager for South Korea.

Sep 08, 2020

DermTech: Michael Howell

DermTech has appointed Michael Howell as CSO, a role in which he will coordinate research, new product development, and clinical validation efforts. Howell has over twenty years of academic and pharmaceutical industry experience. Prior to joining DermTech, he was the translational research lead for inflammation and autoimmunity at Incyte, driving the strategic expansion of Incyte’s pipeline in dermatology and other immunological disorders. Prior to that, he held various other roles within the pharmaceutical industry at Boehringer Ingelheim, Immune Tolerance Network, and MedImmune/AstraZeneca.
 
Howell also served as a faculty member in the Division of Allergy and Immunology at National Jewish Health. He earned a bachelor of science degree in biology from Messiah College and a doctorate in immunology from West Virginia University School of Medicine.
Sep 03, 2020

Syapse: David Pomerantz

Syapse has appointed David Pomerantz as chief commercial officer. Pomerantz joins Syapse from Kantar Health, where he worked for more than a decade including as leader of the RWE Client Partner sales team for the Americas and Europe. He was also responsible for Kantar’s acquisition of Brazilian oncology-focused healthcare consulting firm Evidencias.

Sep 03, 2020

NeoGenomics: Scott Reid

NeoGenomics announced Scott Reid has been promoted to vice president of alliances and companion diagnostics. He was previously the head of strategic alliances and CDx in the Pharma Services department at NeoGenomics. Reid has also served as director of business development at Covance and as business development director at Laboratory Corporation of America Clinical Trials.

Sep 03, 2020

NeuroPointDx: Barbara Handelin, Tony Shuber

NeuroPointDx appointed Barbara Handelin and Tony Shuber as new board members. Both have experience in the development and commercialization of new molecular diagnostic tests. Handelin was founding director of the DNA diagnostics lab at Integrated Genetics, now part of Laboratory Corporation of America, and Shuber was chief technology officer and cofounder of Exact Sciences and Predictive Biosciences.

NeuroPointDx said the appointments signal the expansion of its pipeline of diagnostic and precision medicine offerings in autism and other complex brain disorders, including anxiety and depression.

Sep 02, 2020

Akoya Biosciences: Niro Ramachandran, Gavin Gordon

Akoya Biosciences has appointed Niro Ramachandran as its chief business officer and Gavin Gordon as VP of clinical market development.

Ramachandran previously served as VP of NanoString's spatial biology business unit. Prior to NanoString, he held the role of R&D manager at Life Technologies (now part of Thermo Fisher Scientific). In addition, he cofounded and served as chief technology officer of Auguron.

Prior to Akoya, Gordon held senior level positions at Fluidigm and Thermo Fisher Scientific. He has also served as assistant professor at Harvard Medical School and as a faculty member of Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center.

Sep 02, 2020

Castle Biosciences: Toby Juvenal, Kristen Oelschlager, Bob Cook, Matthew Goldberg

Castle Biosciences has promoted Toby Juvenal as chief commercial officer, Kristen Oelschlager as chief operations officer, Bob Cook as senior vice president of research and development, and Matthew Goldberg as a medical director.

Juvenal has served as the company's senior VP of sales since January 2018, and previously served as VP of sales and marketing since joining Castle Bio in October 2008. He has more than 28 years of sales, sales management, and managed care experience in the pharmaceutical, biotechnology, and diagnostics industries.

Oelschlager has served as the company's senior VP of clinical operations since January 2018, and previously served as VP of clinical operations from 2013 to 2018. She joined the company as executive director of operations in October 2008, and has more than 15 years of experience in clinical nursing, clinical operations services, and clinical research. 

Cook has served as Castle Bio's VP of research and development since July 2019, previously serving as VP of medical affairs and research and development from April 2018 to July 2019, executive director of research and development from June 2015 to April 2018, and manager of scientific relations from February 2011 to June 2015. 

Goldberg perviously served as an assistant professor in dermatology and pathology at the Icahn School of Medicine at Mount Sinai in New York, and will retain his affiliation as an assistant clinical professor of dermatology. Before joining the Mount Sinai dermatology faculty, Goldberg directed dermatopathology education for the MedStar Georgetown/Washington Hospital Center Dermatology Residency Program.
Aug 31, 2020

Axol Bioscience: Liam Taylor

Axol Bioscience has appointed Liam Taylor as its CEO. Taylor most recently served as CFO and then managing director of BBI solutions.

Aug 28, 2020

Cellink: Ido Amit

Cellink said that Ido Amit is joining the company's scientific advisory board. Amit is a researcher in the Immunology Department at the Weizmann Institute of Science in Israel, where he also earned his PhD in biological regulation. He was a postdoctoral fellow at the Broad Institute at Harvard University and the Massachusetts Institute of Technology. Amit's expertise is in the area of single-cell genomic technologies and their application to characterize the immune system, and as such he will guide Cellink's efforts to build a strong product portfolio for single-cell omics analysis, the company said.

Aug 27, 2020

Biocept: Michael Dugan

Biocept has appointed Michael Dugan as chief medical officer and medical director, responsible for medical policy decision-making and operations of Biocept's CLIA-certified laboratory. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics International. Before that, he was senior medical advisor and chief medical officer of Clinical Genomics. He has also served as senior VP of clinical development and medical affairs at Exact Sciences, medical director at Quest Diagnostics Nichols Institute, chief medical officer at BioTheranostics, VP and chief medical officer at Roche Molecular Systems, and VP of pathology services at Genzyme Genetics.

Dugan received a BS in biology from the University of Notre Dame and a medical degree from the University of Arizona College of Medicine. He completed his post-graduate training in the department of pathology at Yale-New Haven Hospital and in the departments of pathology and laboratory medicine at Childrens Hospital Los Angeles and the University of California, Los Angeles.

Aug 27, 2020

Oncocyte: Jennifer Levin Carter

Oncocyte has appointed Jennifer Levin Carter to its board of directors. Carter is a healthcare executive, board member, and entrepreneur and was most recently VP and head of precision health at Integral Health. She has founded and served as CEO at healthcare companies including N-of-One, where she was CEO from 2008 to 2012 and chief medical officer from 2012 until its acquisition by Qiagen in 2019. In addition to her board appointment for Oncocyte, Carter serves as a director of DFP Healthcare Acquisitions and is on the board of directors of home healthcare firm HouseWorks, digital health company eCaring, and the Target Cancer Foundation. She is a founding strategic board member of XSphera Biosciences, and on the directors advisory board at Smilow Cancer Hospital at Yale University. 

Aug 27, 2020

Lucence: Chao Xie

Singapore-based precision oncology company Lucence has appointed Chao Xie as chief data scientist to develop advanced analytics of ultrasensitive liquid biopsy diagnostics for cancer. Xie previously served as head of data science at AirAsia. He won a US Defense Threat Reduction Agency $1M global competition in 2013 for designing an algorithm to rapidly and accurately identify dangerous viruses and bacteria in gene sequencing data.

Aug 26, 2020

Immunovia: Patrik Dahlen and Mats Grahn

Immunovia appointed Patrik Dahlen as its new CEO starting Nov. 1. Dahlen succeeds Mats Grahn, who has been nominated as a member of Immunovia's board.

Dahlen has served as CEO of several diagnostic companies. As CEO of Dako, he implemented a strategic repositioning of the company as a supplier of cancer diagnostics, which resulted in its acquisition by Agilent Technologies for $2.2 billion. As president of life sciences at Perkin Elmer, he was instrumental in building the company's diagnostics business with a niche focus on diagnostic systems for neonatal and prenatal screening.

Pages

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.